Dr Paul P. Doghramji: Prescribing Biosimilars in IBD

Transcript:

Are you or any of your colleagues beginning to prescribe biosimilars?

I haven’t started prescribing biosimilars yet for these diseases. I tend to use brand names more than anything, but sometimes I’m forced to do it because of insurance constraints. As a general rule, we like to use a medication that’s come out by that specific pharma company in that brand name because we know exactly what we’re getting.